SCUBE3 and osteosarcoma: In contrast, SCUBE3 mRNA levels were increased in post-denosumab-treated GCTs compared to untreated tumours and were also high in bone-forming osteoclast-poor osteosarcomas compared to osteoclast-rich osteosarcomas (Fig. 2D, E).